<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540943</url>
  </required_header>
  <id_info>
    <org_study_id>VEG108925</org_study_id>
    <nct_id>NCT00540943</nct_id>
  </id_info>
  <brief_title>Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase I Study of Safety and Pharmacokinetics of Pazopanib in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum
      tolerated dose can be determined. 18 additional patients will be recruited once the maximum
      tolerated dose (MTD) is determined for disease assessment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2007</start_date>
  <completion_date type="Actual">May 3, 2010</completion_date>
  <primary_completion_date type="Actual">May 3, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of the maximum tolerated dose defined as a dose regimen where no more than 1 of 6 subjects experiences a dose limiting toxicity.</measure>
    <time_frame>End of 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics disease assessment</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of irinotecan (if data permit) and AUC, Cmax, tmax, and t1/2 of irinotecan and SN-38 after administration of irinotecan plus cetuximab.</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24), Cmax, tmax, and t1/2 of pazopanib when administered with irinotecan and cetuximab</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24), Cmax, and tmax of cetuximab when administered with irinotecan alone</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24), Cmax, and tmax of cetuximab when administered with irinotecan plus pazopanib.</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of SN-38 AUC(0-24) and irinotecan AUC(0-24) on Cycle 1 Day 1 and on Cycle 2 Day 1.</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (complete response (CR) plus partial response (PR)) will be the primary measure of antitumor activity</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (SD) at 4 months</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Neoplasms, Colorectal</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan and cetuximab in combination with pazopanib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.
buffered saline</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female at least 18 years of age.

          -  Willing and able to sign a written informed consent.

          -  Is either affiliated to or a beneficiary of a social security category

          -  Histologically or cytologically confirmed diagnosis of colorectal cancer. Subjects
             should have metastatic disease which is refractory or relapsed following prior
             treatment.

          -  Documented disease progression after prior treatment with 5-FU, oxaliplatin and
             irinotecan containing regimens.

          -  Complete recovery from surgical or radiotherapy procedures.

          -  Eastern Cooperative Oncology Group performance status of 0 or 1, or Karnofsky score ≥
             70%.

          -  Able to swallow and retain oral medications.

          -  Adequate bone marrow function (absolute neutrophil count greater than or equal to
             1,500/mm3, platelet count greater than or equal to 100,000/mm3, hemoglobin levels
             greater than or equal to 10g/dL).

          -  Adequate renal function as determined by a creatinine clearance greater than 50
             mL/minute calculated by the Cockcroft-Gault Formula. Measured creatinine clearance
             greater than or equal to 50 mL/minute by 24 hour urine collection will be acceptable
             in lieu of a calculated value.

          -  Urine Protein Creatinine (UPC) Ratio of ≤ 1 as assessed in a random or spot urine
             sample.

          -  Adequate hepatic function determined by total bilirubin within the normal range and
             aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT or SGPT)
             less than or equal to 2.5 times the upper limit of normal.

          -  Prothrombin time (PT), international normalized ratio (INR), and partial
             thromboplastin time (PTT) less than or equal to 1.2 times the ULN.

          -  A female subject is eligible to enter and participate in the study if she is:

             ·Non-childbearing potential (i.e., physiologically incapable of becoming pregnant)
             including any woman who:

          -  Has had a hysterectomy, or

          -  Has had a bilateral oophorectomy (ovariectomy), or

          -  Has had a bilateral tubal ligation, or

          -  Is post-menopausal (demonstrate total cessation of menses for greater than or equal to
             1 year).

          -  Childbearing potential, has a negative serum pregnancy test at screening, and agrees
             to one of the following:

          -  An intrauterine device with a documented failure rate of less than 1% per year.

          -  Vasectomized partner who is sterile prior to the subject's entry and is the sole
             sexual partner for that woman.

          -  Complete abstinence from sexual intercourse for 14 days before exposure to
             investigation product, throughout the clinical trial, and for at least 21 days after
             the last dose of investigational product.

          -  Double barrier contraception defined as condom with spermicidal jelly, foam,
             suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.

          -  A male patient with a female partner of childbearing potential is eligible to enter
             and participate in the study if he uses a barrier method of contraception or
             abstinence during the study.

          -  Predicted life expectancy of at least 12 weeks.

          -  Able to understand and comply with protocol requirements and instructions and intends
             to complete the study as planned.

        Exclusion criteria:

          -  Has participated in any study using an investigational drug during the previous 28
             days.

          -  Has had any major surgery, chemotherapy, investigational agent, or radiotherapy within
             the last 28 days and/or not recovered from prior therapy.

          -  Any history of grade III toxicity related to prior treatment with anti VEGF compound
             other than grade 3 hypertension subsequently controlled with antihypertensive agents.

          -  Has received prior treatment with pazopanib / investigational anti-angiogenic
             compounds or cetuximab. Prior treatment with Avastin is permitted. Known
             contraindications to the use of irinotecan and cetuximab.

          -  Unable to tolerate 180mg/m2 of irinotecan every two weeks during previous treatment.

          -  Is unable to discontinue prohibited medications, as stipulated in the protocol for 14
             days prior to Visit 1 and for the duration of the study

          -  Has received Amiodarone for arrythmias within the last 6 months prior to Visit 1

          -  Has known allergy to penicillin.

          -  Women who are pregnant or lactating.

          -  Poorly controlled hypertension (systolic blood pressure [SBP] of 140 mmHg or higher,
             or diastolic blood pressure [DBP] of 90 mmHg or higher). Initiation or adjustment of
             blood pressure medication is permitted prior to study entry provided the subject has 2
             consecutive blood pressure readings less than 140/90 mmHg, each separated by a minimum
             of 24 hours. These readings need to be collected prior to the first dose.

          -  Corrected QT (QTc) prolongation defined as a QTc interval greater than or equal to 480
             msec and a prior history of cardiovascular disease, arrhythmias, or significant ECG
             abnormalities.

          -  Has Class III or IV heart failure as defined by the New York Heart Association
             functional classification system.

          -  Arterial thrombi, myocardial infarction, admission for unstable angina, uncontrolled
             or symptomatic arrhythmia, cardiac angioplasty, or stenting within the last 6 months.

          -  Any history of cerebrovascular accident (CVA), or pulmonary embolism within the last 6
             months.

          -  History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf
             vein thrombosis). Note: Patients with recent DVT who have been treated with
             therapeutic anti-coagulant agents (excluding therapeutic warfarin) for at least 6
             weeks are eligible.

          -  Current use of therapeutic warfarin. NOTE: Low molecular weight heparin and
             prophylactic low-dose warfarin (no more than 1mg per day) are permitted. PT/PTT and
             INR must be within 1.2 times the upper limit of normal.

          -  Known history of leptomeningeal or brain metastases. NOTE: Computed tomography or
             magnetic resonance imaging (MRI) scans are not required to rule out central nervous
             system metastases unless the subject is exhibiting neurologic signs or symptoms. If,
             however, CT or MRI scans are performed and document central nervous system disease,
             the subject is ineligible, regardless of whether neurologic signs or symptoms are
             present.

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition
             (including laboratory abnormalities) that could interfere with subject safety or
             obtaining informed consent.

          -  History of mal-absorption syndrome, disease significantly affecting gastrointestinal
             function or major resection of the stomach or small bowel that could affect
             absorption, distribution, metabolism, or excretion of study drugs.

          -  History of any unresolved bowel obstruction or diarrhea.

          -  The subject has a known immediate or delayed hypersensitivity reaction or idiosyncrasy
             to drugs chemically related to the study drug, irinotecan, or cetuximab, unless
             enrolment is approved by the GSK Medical Monitor following discussion with the
             Investigator.

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

          -  Is on any specifically prohibited medication or requires any of these medications
             during treatment with pazopanib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/VEG108925?search=study&amp;study_ids=VEG108925#rs</url>
    <description>Results for study VEG108925 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>irinotecan,</keyword>
  <keyword>pazopanib,</keyword>
  <keyword>Colorectal cancer,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

